Table 1 Baseline characteristics of the study cohort. Per-protocol dataset with full strain assessment
Total | ALFA | ETEL | p-value | |
|---|---|---|---|---|
N = 48 | N = 23 | N = 25 | ||
Age | 62 (11) | 61 (7) | 62 (13) | 0.88 |
Male sex | 75% | 83% | 68% | 0.24 |
Diabetes | 46% | 48% | 44% | 0.79 |
Hypertension | 98% | 96% | 100% | 0.29 |
Hyperlipidemia | 52% | 52% | 52% | 0.99 |
Coronary artery disease | 58% | 70% | 48% | 0.13 |
Heart failure | 27% | 22% | 32% | 0.42 |
Peripheral arterial disease | 21% | 22% | 20% | 0.88 |
Cause of ESRD | 0.59 | |||
Diabetic nephropathy | 27% | 35% | 20% | |
Hypertensive nephropathy | 15% | 13% | 16% | |
Vascular nephropathy | 19% | 17% | 20% | |
Polycystic kidney disease | 12% | 17% | 8% | |
Glomerulonephritis | 10% | 9% | 12% | |
Other kidney disease | 17% | 9% | 24% | |
Months on dialysis | 11 (10) | 12 (11) | 10 (9) | 0.48 |
Dialysis access (fistula) | 77% | 83% | 72% | 0.38 |
Baseline CMR parameters | ||||
LVEF | 51 (9) | 50 (10) | 53 (7) | 0.39 |
LV CI | 3.3 (0.8) | 3.3 (0.9) | 3.3 (0.6) | 0.75 |
LV GLS | − 21 (5) | − 21 (5) | − 22 (4) | 0.86 |
LV GCS | − 33 (8) | − 32 (8) | − 33 (7) | 0.39 |
LV GRS | − 22 (6) | − 21 (7) | − 23 (4) | 0.45 |
RV GLS | − 24 (6) | − 23 (6) | − 24 (6) | 0.56 |
LA EF | 43 (14) | 41 (14) | 44 (13) | 0.49 |
LA GLS | 23 (13) | 22 (16) | 24 (11) | 0.60 |
LA GCS | 23 (11) | 21 (10) | 25 (11) | 0.21 |
T1 time (ms) | 1018 (40) | 1023 (43) | 1014 (40) | 0.47 |
T2 time (ms) | 50 (2.5) | 50 (3.0) | 50 (2.0) | 0.92 |